2006
DOI: 10.1016/j.apradiso.2005.08.011
|View full text |Cite
|
Sign up to set email alerts
|

Studies on the production and quality assurance of miniature 125I radioactive sources suitable for treatment of ocular and prostate cancers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0
1

Year Published

2009
2009
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(10 citation statements)
references
References 8 publications
0
9
0
1
Order By: Relevance
“…1] after quality assurance tests[5] were supplied by Radiopharmaceuticals Division of Bhabha Atomic Research Center, Mumbai (BARC). [67] Precise individual seed activity is a prerequisite for accurate dose calculations. In order to preclude dosimetric errors in the treatment planning study, seeds from only one batch were used in each case.…”
Section: Methodsmentioning
confidence: 99%
“…1] after quality assurance tests[5] were supplied by Radiopharmaceuticals Division of Bhabha Atomic Research Center, Mumbai (BARC). [67] Precise individual seed activity is a prerequisite for accurate dose calculations. In order to preclude dosimetric errors in the treatment planning study, seeds from only one batch were used in each case.…”
Section: Methodsmentioning
confidence: 99%
“…At the end of 48 hours, the total leached out radioactivity was assayed to determine the leachability of bare sources should be less than 0.01% of the total seed activity. The physico-chemical adsorption method [14] adapted by us was found to achieve this limit and thus complied with regulatory norms.…”
Section: Leachabilitymentioning
confidence: 98%
“…The variation in OD values at different positions should be ±10 %. Sources prepared by the physico-chemical adsorption methodology [14] in our laboratory has variation within ± 5% (Fig.12). …”
Section: Uniformity Of Activitymentioning
confidence: 99%
See 1 more Smart Citation
“…The Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC) has successfully developed a technology for the production of indigenous 125 I brachytherapy sources for the treatment of ocular cancer patients in India[78] and assessed its dosimetry. [9] We describe our initial experience and learning curve using ‘BARC 125 I Ocu-Prosta seed’ for the treatment of intraocular tumors.…”
mentioning
confidence: 99%